As pioneers in integration site analysis (ISA), GeneWerk is forging the path for safer gene therapies. Leveraging our 20+ years of experience in integration site analysis for lentiviral and AAV gene therapies, we support clients across the globe at every stage of the vector safety assessment process.
As novel gene therapies enter development pipelines, regulatory bodies adapt their guidelines to ensure their continued safety. Actively and passively integrating (viral) vectors may trigger adverse effects by undirected or unintended integration into the genome of the target cell.
Integration site analysis (ISA) is the key tool to assess the biosafety of gene therapy vectors and the clonal tracking fate of genetically modified cells in vivo. According to FDA and EMA guidance for viral-vector-based therapies, once the vector integration is confirmed, integration site analysis should be undertaken to monitor integration frequency and site identification.
At GeneWerk, we have developed a comprehensive set of tools for regulatory-compliant, genome-wide integration site analysis. Combining streamlined PCR- and sequencing-based approaches with proprietary bioinformatics pipelines, we can determine the integration site position and frequency of your viral vector with unmatched precision and sensitivity.
Shearing Extension Primer Tag Selection Ligation-Mediated PCR (S-EPTS/LM PCR) is the world’s first validated approach for genome-wide integration site analysis. Having been successfully employed in multiple clinical trials and regulatory filings, S-EPTS/LM PCR is GeneWerk’s most recommended assay for ISA.
Target enrichment sequencing (TES) is our most comprehensive assay to simultaneously detect vector integration sites, vector integrity, and vector copy number in a single reaction.
Linear amplification-mediated PCR (LAM-PCR), developed by GeneWerk’s founders, has been the gold standard for ISA for over 20 years. (nr)LAM-PCR – its non-restrictive (nr) variation – is best suited for the detection of rare integration sites.
Read our latest press releases and announcements below.
GeneWerk will expand capabilities to meet rapidly growing demand for cell and gene therapy...